HR+/HER2- Advanced or Metastatic Breast Cancer

2 clinical trials · Condition

Record	Firm	Date
A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy (NCT05853432)	Novartis Pharmaceuticals	2022-03-16

Every clearance here is in the API, with alerts when new ones post.